Drug Type Nanobody |
Synonyms- |
Target |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Synthekine, Inc.Startup |
Active Organization Synthekine, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Immune System Diseases | Discovery | - | Synthekine, Inc.Startup | 10 Feb 2022 |
Infectious Diseases | Discovery | - | Synthekine, Inc.Startup | 10 Feb 2022 |
Inflammation | Discovery | - | Synthekine, Inc.Startup | 10 Feb 2022 |
Neoplasms | Discovery | - | Synthekine, Inc.Startup | 10 Feb 2022 |
Nervous System Diseases | Discovery | - | Synthekine, Inc.Startup | 10 Feb 2022 |
Nutritional and Metabolic Diseases | Discovery | - | Synthekine, Inc.Startup | 10 Feb 2022 |
Rare Diseases | Discovery | - | Synthekine, Inc.Startup | 10 Feb 2022 |
Skin and Musculoskeletal Diseases | Discovery | - | Synthekine, Inc.Startup | 10 Feb 2022 |